NasdaqGM - Delayed Quote USD

Rhythm Pharmaceuticals, Inc. (RYTM)

39.97 +0.29 (+0.73%)
At close: June 7 at 4:00 PM EDT
40.70 +0.73 (+1.83%)
After hours: June 7 at 5:39 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
91,926.00
77,428.00
23,638.00
3,154.00
--
--
Cost of Revenue
10,688.00
9,302.00
2,133.00
599.00
--
--
Gross Profit
81,238.00
68,126.00
21,505.00
2,555.00
--
--
Operating Expense
352,951.00
252,483.00
200,662.00
172,614.00
136,575.00
--
Operating Income
-271,713.00
-184,357.00
-179,157.00
-170,059.00
-136,575.00
--
Net Non Operating Interest Income Expense
-2,035.00
53.00
-1,172.00
447.00
2,579.00
--
Other Income Expense
741.00
190.00
-790.00
100,000.00
--
--
Pretax Income
-273,007.00
-184,114.00
-181,119.00
-69,612.00
-133,996.00
--
Tax Provision
864.00
564.00
--
--
--
--
Net Income Common Stockholders
-273,871.00
-184,678.00
-181,119.00
-69,612.00
-133,996.00
--
Diluted NI Available to Com Stockholders
-273,871.00
-184,678.00
-181,119.00
-69,612.00
-133,996.00
--
Basic EPS
-4.63
-3.20
-3.47
-1.40
-3.04
--
Diluted EPS
-4.63
-3.20
-3.47
-1.40
-3.04
--
Basic Average Shares
58,531.77
57,673.13
52,120.70
49,600.29
44,127.22
--
Diluted Average Shares
58,531.77
57,673.13
52,120.70
49,600.29
44,127.22
--
Total Operating Income as Reported
-271,713.00
-184,357.00
-179,157.00
-170,059.00
-136,575.00
--
Total Expenses
363,639.00
261,785.00
202,795.00
173,213.00
136,575.00
--
Net Income from Continuing & Discontinued Operation
-273,871.00
-184,678.00
-181,119.00
-69,612.00
-133,996.00
--
Normalized Income
-273,871.00
-184,678.00
-181,119.00
-69,612.00
-133,996.00
--
Interest Income
13,551.00
13,945.00
4,029.00
447.00
2,579.00
--
Interest Expense
15,586.00
13,892.00
5,201.00
--
--
--
Net Interest Income
-2,035.00
53.00
-1,172.00
447.00
2,579.00
--
EBIT
-257,421.00
-170,222.00
-175,918.00
-69,612.00
-133,996.00
--
EBITDA
-255,715.00
-168,464.00
-174,246.00
-68,454.00
-133,306.00
--
Reconciled Cost of Revenue
10,688.00
9,302.00
2,133.00
599.00
--
--
Reconciled Depreciation
1,706.00
1,758.00
1,672.00
1,158.00
690.00
--
Net Income from Continuing Operation Net Minority Interest
-273,871.00
-184,678.00
-181,119.00
-69,612.00
-133,996.00
--
Normalized EBITDA
-255,715.00
-168,464.00
-174,246.00
-68,454.00
-133,306.00
--
Tax Rate for Calcs
0.00
0.00
--
--
--
--
12/31/2019 - 10/9/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MLTX MoonLake Immunotherapeutics
41.67
-1.81%
 
NUVL Nuvalent, Inc.
79.18
-2.98%
 
RVMD Revolution Medicines, Inc.
40.34
+0.47%
 
DNLI Denali Therapeutics Inc.
20.77
-2.53%
 
CRNX Crinetics Pharmaceuticals, Inc.
44.71
-2.47%
 
IDYA IDEAYA Biosciences, Inc.
38.01
-4.09%
 
KRYS Krystal Biotech, Inc.
164.42
-0.76%
 
VERA Vera Therapeutics, Inc.
38.50
+1.26%
 
AGIO Agios Pharmaceuticals, Inc.
47.61
-0.40%
 
APGE Apogee Therapeutics, Inc.
41.69
-1.01%